A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.

Sandip P PatelMegan OthusYoung Kwang ChaeFrancis J GilesDonna E HanselPreet Paul SinghAnnette FontaineManisha H ShahAnup Kasi Loknath KumarTareq Al BaghdadiMarc MatranaZoran GatalicaWolfgang Michael KornJourdain HaywardChristine McLeodHelen X ChenElad SharonEdward MayersonChristopher W RyanMelissa PletsCharles D BlankeRazelle Kurzrock

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Ipilimumab plus nivolumab demonstrated a 44% ORR in patients with nonpancreatic high-grade neuroendocrine carcinoma, with 0% ORR in low/intermediate grade disease.

Keyphrases

phase ii
neuroendocrine tumors
high grade
clinical trial
open label
phase iii
low grade
placebo controlled
double blind
study protocol
randomized controlled trial